肿瘤细胞治疗研究
ALL SOURCES
Functional genomics-guided design of CAR-T and CAR-NK therapies in hematological malignancies: aligning cellular engineering with immune escape and mi
一种以耐药为导向的策略可能有助于使工程化细胞疗法的设计与高危血液系统恶性肿瘤中治疗失败的主要机制相一致。未来的 CAR-T 和 CAR-NK 开发不应仅仅增加工程化复杂性，而应将每一处改造与可测量的耐药机制、可行的生物标志物以及可在临床中检验的获益联系起来。在耐药匹配的细胞免疫治疗能够广泛整合进入临床实践之前，前瞻性验证、基因组安全性评估、生产一致性以及长期监测将是必不可少的。
Injectable Hydrogels for Breast Cancer Therapy: From Tumor Microenvironment-Responsive and Actively Targeted Drug Delivery to Immunotherapy and Theran
乳腺癌治疗仍面临诸多挑战，包括局部复发、全身毒性、肿瘤异质性、耐药和免疫抑制。
Beyond exhaustion: T cell fitness for next generation of immunotherapy for hematological cancer.
T细胞导向的免疫疗法已改变了血液系统恶性肿瘤的治疗，但持久获益仍受限于复发、持续性差、免疫重建不完全和感染。
Next-generation CAR-T engineering for colorectal cancer: integrating targets, tumor microenvironment barriers, and emerging strategies.
结直肠癌（CRC）的嵌合抗原受体（CAR）-T细胞治疗面临三大障碍：抗原异质性、脱靶毒性和疗效-安全性权衡。
From Bench to Bedside: Emerging Paradigms in CAR-T Cell Therapy for Solid Malignancies.
免疫治疗，尤其是CAR-T 细胞疗法，已经彻底改变了血液系统恶性肿瘤和自身免疫性疾病的治疗。
Novel strategy for tumor immunotherapy using FITC-folate bispecific adapter bridged CAR immune cell cocktails.
由CAR中性粒细胞和CAR NK细胞组成的鸡尾酒生物材料共同产生协同抗肿瘤效应：中性粒细胞增强TME调节，NK细胞提供靶向细胞毒性。
Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment.
自然杀伤（NK）细胞作为先天免疫的关键介质，在抗肿瘤免疫中发挥重要作用。
A new era of natural killer cell immunotherapy in tumor treatment: latest advances and cutting-edge perspectives from basic research to clinical pract
早在 1863 年，Virchow 就观察到癌症常发生于慢性炎症部位。
CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells.
自体嵌合抗原受体（CAR）-T细胞的临床应用受到可靶向癌症类型有限以及制备过程耗时且成本高昂的制约。
CD38-Specific CAR Integrated into CD38 Locus Driven by Different Promoters Causes Distinct Antitumor Activities of T and NK Cells.
这些结果支持了 CD38 CAR-T/NK 对 T-ALL 的疗效，并证明“二合一”策略能够解决自相残杀问题并增强肿瘤清除，为临床转化铺平了道路。
MEMBER ACCOUNT
登录成功会直接打开下一页。
